Du är här

2016-01-29

Ablynx: ABLYNX TO RECEIVE €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY

GHENT, Belgium, 29 January 2016
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced that Boehringer Ingelheim has administered the first dose in a
Phase I dose escalation study with the half-life extended bi-specific
anti-VEGF/Ang2 Nanobody®in adult patients with advanced solid tumors,
triggering an €8 million milestone payment to Ablynx. The aim of the study is
to evaluate the safety profile and dosing schedule for this Nanobody.

The anti-VEGF/Ang2 Nanobody was discovered and developed as part of the
Strategic Alliance between both parties, signed in September 2007. This
Nanobody blocks both vascular endothelial growth factor (VEGF) and
angiopoietin-2 (Ang2), important proteins which are involved in the formation
of new blood vessels from pre-existing vessels (angiogenesis), a vital
mechanism in the growth of tumours.

Dr Edwin Moses, CEO of Ablynx, commented:
"We are very pleased that the first bi-specific Nanobody, as part of our
collaboration with Boehringer Ingelheim, has entered clinical development.
The formatting flexibility and ability to link different Nanobodies together
to bind to different proteins and/or epitopes is a key feature of our
technology and is of particular interest in cancer drug development. We are
looking forward to seeing more of these innovative product candidates enter
the clinic in the future."

Theresults from the pre-clinical study have been presentedby Boehringer
Ingelheim at the 8thEuro Global Summit on Cancer Therapy and demonstrated
that this bi-specific Nanobody potently inhibits VEGF and Ang2 signalling in
multiplein vivo
cancer models and strongly impairs proliferation and survival of human
endothelial cells. In addition, the bi-specific Nanobody showed superior
efficacy as compared to inhibition of the individual pathways by the
reference monoclonal antibody drugs. The Nanobody was also found to be well
tolerated in cynomolgus monkeys.

About Strategic Alliance between Boehringer Ingelheim and Ablynx

InSeptember 2007, Ablynx and Boehringer Ingelheim entered into a Strategic
Alliance on the discovery, development and commercialisation of Nanobody
therapeutics across a range of diseases, including oncology, immunology,
respiratory and vascular diseases. The agreement allows for potential
milestone payments of up to €125 million plus royalties to Ablynx for each
Nanobody which reaches the market. Boehringer Ingelheim is exclusively
responsible for the development, manufacturing and commercialisation of any
products resulting from the collaboration. Ablynx retains certain
co-promotion rights in Europe. To date, Ablynx has earned>€75 million in cash
from this Strategic Alliance and in addition to the anti-VEGF/Ang2 Nanobody
there are a number of other programmes advancing through pre-clinical
development, all fully funded by Boehringer Ingelheim.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has approximately40 proprietary and partnered programmesin development in
various therapeutic areas including inflammation, haematology,
immuno-oncology, oncology and respiratory disease. The Company has
collaborations with multiple pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA,
Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found
onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Instinctif Partners:

Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e:ablynx@instinctif.com

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e:ablynx@instinctif.com

Pdf version of the press release
http://hugin.info/137912/R/1981965/726219.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1981965

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.